Is Fifty 1 Labs, Inc. (FITY) a Buy, Sell, or Hold?
OTC : FITY
Fifty 1 Labs, Inc. — News
$0.0003 USD
$0.0 (-25.0%)
- Volume
- 40.67M
- Average Volume
- 17.29M
- Market Capitalization
- $171.56K
- P/E Ratio
- -4.25
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $0.00
| Source | Headline |
|---|---|
|
Fifty 1 Labs Outlines Planned U.S. Telehealth Peptide Services Platform
Model expected to include digital intake, clinician evaluation, prescription routing, monitoring coordination, and subscription-based patient support VANCOUVER, BC / ACCESS Newswire / August 7, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) today provided an overview of its planned U.S. - focused telehealth peptide services platform. The Company intends to develop a patient-facing service model that complements its peptide science and commercialization strategy while remaining separate from investigational clinical-development programs. accessnewswire.com - 2026-08-07 09:00:00 |
|
Fifty 1 Labs Announces Strategic Evolution into Peptide Biotechnology and Telehealth
Company outlines dual platform spanning peptide R&D, AI-enabled discovery, and planned U.S. telehealth peptide services VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Fifty 1 Labs, Inc. (OTCID:FITY) (the "Company" or "Fifty 1 Labs") today announced that it is positioning itself as a peptide biotechnology and telehealth company focused on advancing peptide science, musculoskeletal ("MSK") health, recovery, and evidence-driven product innovation. The Company's emerging strategy integrates three complementary areas: peptide research and development, AI-enabled discovery workflows, and a planned U.S.-focused telehealth peptide services platform. accessnewswire.com - 2026-07-10 10:00:00 |
